MetaVia Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-14 | -0.75 | -0.79 | -4.64% |
| 2025-11-06 | -2.75 | -1.54 | +44.00% |
| 2025-08-07 | -2.46 | -2.86 | -16.42% |
| 2025-05-14 | -7.15 | -3.96 | +44.62% |
| 2025-03-20 | -8.14 | -3.52 | +56.76% |
| 2024-11-07 | -8.03 | -6.05 | +24.66% |
| 2024-08-14 | -12.36 | -20.35 | -64.69% |
| 2024-05-09 | -39.93 | -14.52 | +63.64% |
| 2024-03-28 | -8.63 | -25.08 | -190.45% |
| 2023-11-13 | -9.68 | -7.92 | +18.18% |
| 2023-08-09 | -11.44 | -1.76 | +84.62% |
| 2023-05-12 | -55.44 | -5.28 | +90.48% |
| 2022-11-14 | -448.80 | -308.00 | +31.37% |
| 2021-11-15 | -475.20 | -422.40 | +11.11% |
| 2021-08-16 | -396.00 | -475.20 | -20.00% |
| 2021-05-17 | -422.40 | -396.00 | +6.25% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| MTVA | +97.22% | +82.05% | -66.27% | -60.28% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +94.25% | +86.69% | -62.83% | -72.97% |